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Abstract
Background: Research is fundamental to high-quality care, but concerns have been raised about whether health
research is conducted in the populations most affected by high disease prevalence. Geographical distribution of
research activity is important for many reasons. Recruitment is a major barrier to research delivery, and undertaking
recruitment in areas of high prevalence could be more efficient. Regional variability exists in risk factors and
outcomes, so research done in healthier populations may not generalise. Much applied health research evaluates
interventions, and their impact may vary by context (including geography). Finally, fairness dictates that publically
funded research should be accessible to all, so that benefits of participating can be fairly distributed. We explored
whether recruitment of patients to health research is aligned with disease prevalence in England.
Methods: We measured disease prevalence using the Quality and Outcomes Framework in England (total long-
term conditions, mental health and diabetes). We measured research activity using data from the NIHR Clinical
Research Network. We presented descriptive data on geographical variation in recruitment rates. We explored
associations between the recruitment rate and disease prevalence rate. We calculated the share of patient
recruitment that would need to be redistributed to align recruitment with prevalence. We assessed whether
associations between recruitment rate and disease prevalence varied between conditions, and over time.
Results: There was significant geographical variation in recruitment rates. When areas were ranked by disease
prevalence, recruitment was not aligned with prevalence, with disproportionately low recruitment in areas with
higher prevalence of total long-term and mental health conditions. At the level of 15 local networks, analyses
suggested that around 12% of current recruitment activity would need to be redistributed to align with disease
prevalence. Overall, alignment showed little change over time, but there was variation in the trends over time in
individual conditions.
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Conclusions: Geographical variations in recruitment do not reflect the suitability of the population for research.
Indicators should be developed to assess the fit between research and need, and to allow assessment of
interventions among funders, researchers and patients to encourage closer alignment between research activity
and burden.
Keywords: Research activity, Recruitment, Equity
Background
Research is fundamental to high-quality health care, pro-
viding the evidence-base for health policy and treatment
delivery. In addition, taking part in research is itself
associated with better performance among health care
organisations [1, 2], as well as being a positive experi-
ence for patients [3].
Nevertheless, delivering research is challenging, with
various factors impacting on patient recruitment and re-
tention [4]. Difficulties with recruitment may be greater in
certain contexts, such as deprived settings [5] and among
ethnic minorities [6]. Equally, barriers may reflect the
characteristics of organisations, in terms of their expertise
and research infrastructure. Organisations may focus on
populations that are easier to recruit, ignoring populations
that are considered ‘hard to reach’ [7]. These barriers and
perceptions mean that the patients recruited into health
research may not accurately reflect the populations to
which the results are expected to apply [8, 9], leading to
concerns about ‘research waste’ [10].
England is unique in having a national research infra-
structure (the NIHR Clinical Research Network) that
provides national coverage in opportunities for research
participation [11, 12]. The network comprises 15 Local
Clinical Research Networks (LCRNs) covering England.
This network has been responsible for recruitment of
several million patients since its inception. This network
provides support to interventional and observational
studies across 30 specialties, meeting the costs of staff,
facilities, equipment and support services. Studies eli-
gible for support include medical studies, health services
research, public health and social care.
Although the total number of recruits represents a key
measure of the performance of a research network, it is
equally critical to ensure that the patients recruited are
representative of the wider population [13]. Although the
network has national coverage in principle, barriers to re-
cruitment mean that primary research (involving patients
consenting to take part) rarely approaches the national
coverage possible with routine administrative data. This
has led to concerns about the degree to which health re-
search is ‘conducted with and in the populations most af-
fected’ [14], i.e. that the geographical distribution of
research activity does not reflect the underlying prevalence
of conditions in the population.
The prevalence of a disorder is a key driver of the
impact of disease on local populations. Demographic
shifts mean that disorders are increasingly prevalent
among older populations [15] and such populations
are increasingly found in rural and coastal areas [16].
In contrast, research may be clustered around loca-
tions associated with research units, major hospitals
and universities.
Conventionally, the geographical distribution of re-
search activity has not been seen as critical to recruit-
ment of a representative sample of patients. As long
as the characteristics of the recruited sample reflect
the underlying population, in principle it should not
matter where those patients have been recruited. Al-
though true in principle, there is good evidence that
recruited patients do not generally reflect the underlying
population [8, 9, 17, 18]. We argue that geographical
distribution of recruitment may be important for a num-
ber of reasons.
First, recruitment is a major barrier to delivery of
research [19]. All other things being equal, undertak-
ing recruitment in areas of high prevalence could be
more efficient, as there will be more people to screen
for eligibility.
Secondly, regional variability exists in the UK in risk
factors and outcomes, with the North-South divide in
premature mortality being a prime example [20]. Two
thirds of this divide have been attributed to measured
deprivation, but one third is likely due to other factors:
cultural differences, health-related behaviour, or social
fragmentation [21]. Research done in healthier popula-
tions may not generalise to populations facing greater
challenges to health and well-being.
Thirdly, a significant proportion of applied health re-
search is concerned with the evaluation of interventions,
and the impact of interventions may vary according to
context [22–24].
Finally, fairness dictates that publically funded research
should be accessible to all. Only in this way can the add-
itional benefits of participating in research (such as im-
proved quality of care and patient outcomes) be made
accessible to all [1, 2].
A strength of the research infrastructure in England is
its focus on performance measurement, as the numbers
of patients recruited is a core metric, and accurate
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recruitment data are available nationally over time. We
used these data to explore the following research
questions:
1. Is patient recruitment aligned with disease
prevalence in England? How does the alignment
vary across clinical specialities?
2. Is alignment getting better or worse over time?
Methods
Measures of recruitment
We analysed data on research that took place between
2013 and 2018 in England, obtained from NIHR Clinical
Research Network Coordinating Centre (CRNCC) Busi-
ness Intelligence for recruitment to NIHR portfolio stud-
ies in England, which includes trials and observational
studies. Studies are assigned to clinical specialties (https://
www.nihr.ac.uk/nihr-in-your-area/specialties.htm). Ethical
approval was not needed for this secondary analysis.
We examined data at two levels: the 15 LCRNs which
are the primary administrative units of the network, and
the 195 clinical commissioning groups (CCGs) in Eng-
land in 2018 (NHS organisations which plan services for
particular geographies). CCGs can be mapped into the
smaller number of LCRNs.
Patients recruited to studies on the network are
assigned to one of the 15 regional LCRNs. Ideally, re-
cruitment data would be based on the place of residence
of each recruit, which would be matched to prevalence
data on a similar basis. However, location of patient
recruitment is recorded, not their home address, so the
mapping of patients to units of analysis is not exact.
Around 80% of recruitment is associated with a hospital
Trust and can be reliably matched to LCRNs only.
Around 20% of the recruitment is in primary care
settings and can be reliably matched both to LCRNs and
CCGs. We conducted an approximate mapping of
hospital Trust recruitment data to CCGs, based on the
location of patient recruitment, but this mapping will
tend to attribute recruitment to CCGs hosting major
research and tertiary centres. We therefore had three
sets of data with different strengths and weaknesses (see
Table 1). We present analysis of each data set and con-
sider the consistency of results.
Measures of disease prevalence
Our measure of disease prevalence was data from the
Quality and Outcomes Framework (QOF) disease regis-
ters in general practice [25] from 2013/14 to 2017/18.
These registers are comprehensive and of acceptable
quality [26]. QOF is the largest national primary care in-
centive scheme worldwide and even though participation
is voluntary, around 95% of practices participate [25].
We examined data for all long-term conditions combined
and separately for mental health and diabetes. The analysis
of all conditions provides a broad overview of the relation-
ship between disease prevalence and recruitment. Examin-
ing specific conditions allows us to explore whether those
relationships vary in different diseases. Diabetes and mental
health are both high-prevalence conditions important to
health policy. Mental health research funding is known to
be poorly matched to burden [27, 28].
For analysis of all long-term conditions, we used data on
patients with the following conditions: atrial fibrillation,
asthma, cancer, coronary heart disease, chronic kidney
disease, chronic obstructive pulmonary disease, dementia,
depression, diabetes, epilepsy, heart failure, hypertension,
limiting disabilities, severe mental health, obesity, osteo-
porosis, peripheral arterial disease, rheumatoid arthritis,
and stroke. For mental health, we combined data on com-
mon mental disorders (depression) and severe mental dis-
orders (psychosis, schizophrenia and bipolar disorder). For
each unit, we calculated prevalence by using the sum on
the relevant disease registers over the total population, for
each relevant time period. Multimorbidity is common, es-
pecially among older patients [15]. We used an aggregate
measure of morbidity, adding separate condition preva-
lence estimates (assuming, therefore, that the effects of
multiple conditions are additive and that each condition is
equally important in terms of overall disease prevalence).
Table 1 Data types and their strengths and weaknesses
Data type Scope Accuracy Granularity
Data on recruitment by hospital Trusts
and primary care aggregated into CCGs
Comprehensive Approximate Higher
All CRN recruitment data included Recruitment from hospital
trusts attributed to CCG based
on location
Data available across 195 CCGs
Hospital trust and primary care
recruitment data matched to LCRNs
Comprehensive Accurate Lower
All CRN recruitment data included Data aggregated to 15 LCRNs
Data on recruitment by primary
care aggregated into CCGs
Partial Accurate Higher
All primary care data, but around 20%
of CRN recruitment data included
Data available across 195 CCGs
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We measured disease prevalence at the LCRN and CCG
levels. QOF data were available at the practice level and were
attributed to both the CCG and LCRN levels. QOF data are
provided each year and allow for CCG mergers that occurred
throughout our study period. However, the mapping of study
recruits from secondary care was based on 2018 CCG areas
(n= 195). For this reason, QOF data prior to 2018 were ag-
gregated into the larger 2018 merged CCGs for the whole
study period. Data on disease burden were complete for all
CCGs in each year. All QOF data were obtained from NHS
Digital for the study period 2013–2018 [25].
Data analysis
Is patient recruitment aligned with disease prevalence
in England? How does the alignment vary across
clinical specialities?
We conducted this analysis in two phases. First, we
assessed whether there was substantial geographical
variation in the recruitment rate across CCGs and
LCRNs.
We calculated the recruitment rate as the number of
recruits divided by the number of people within each
disease group (all long-term conditions, mental health
and diabetes). We produced maps to illustrate the geo-
graphical distribution of recruitment.
We calculated a ‘redistribution index’ to quantify the
share of total recruits that would have to be redistribu-
ted between over-recruiting to under-recruiting areas to
achieve equal shares of recruitment and disease preva-
lence. To assess redistribution, we used the absolute
value of difference between the actual and the equitable
number of recruits across each area (see Fig. 1 for details
of the calculations).
Fig. 1 Calculation of the redistribution index
Bower et al. BMC Medicine          (2020) 18:133 Page 4 of 11
In the second set of analyses, we explored whether
there was a systematic association between the recruit-
ment rate and the disease prevalence rate. We calculated
the prevalence rate as the number of people with the
condition divided by the population of the area (when
we are combining more than one health condition, this
measure can exceed one in areas with high levels of dis-
ease). We divided the 195 CCGs into quintiles of the
prevalence rate to simplify presentation. We ranked
units (CCG quintiles or individual LCRNs) from low to
high based on the prevalence rate. We used bar charts
for CCGs and LCRNs, to show whether the recruitment
rate varied at different levels of the prevalence rate.
We present separate analyses of all long-term condi-
tions, mental health and diabetes, to explore whether the
patterns found across conditions were replicated in indi-
vidual conditions.
Is alignment getting better or worse over time?
To capture change over time, we used concentration
curves [29]. A concentration curve plots the cumulative per-
centage of one variable against the cumulative percentage of
the sample, ranked by another variable. Concentration
curves are used to represent the extent of inequity, captured
by divergence from the 45 degree line (line of equity).
We plotted the cumulative recruitment rate within
each of our disease groups against the cumulative pro-
portion of our geographical units (CCGs or LCRNs),
ranked from the lowest to highest prevalence. If recruit-
ment rate is constant across geographical units with dif-
ferent prevalence rates, the curve will be at the line of
equality [30]. The curve lies above the 45° line, when
there is a disproportionate concentration of recruitment
in lower prevalence areas, and below the line when the
opposite is true.
We plotted concentration curves and calculated the
related redistribution indices for our three groups of
conditions for each year (2013/14 to 2017/18) to provide
a visual assessment of change over time. We also ran a
time series regression with the redistribution index for
each disease group as the dependent variable and time
as the independent variable and to test whether the lin-
ear trend in the redistribution index was statistically dif-
ferent from zero.
Results
We analysed our three groups of conditions (all long-
term conditions, mental health and diabetes) using the
three data types identified in Table 1.
Is recruitment aligned with disease prevalence in
England? How does the alignment vary across clin-
ical specialities?
Table 2 shows the recruitment rate per 1000 people
with the condition for our three disease groups. There
was significant variation in recruitment rates across
different geographical areas. For example, using all data
and all conditions, 25% of CCGs reported only a quarter
of the mean recruitment rate across England (5.74 per
1000 compared to 19.56 per 1000) and 10% of CCGs
had nearly double the mean rate. Similar relationships
were found when using data on primary care recruit-
ment only (for example, 25% of CCGs had rates of 1.19
or less per 1000, compared to a mean of 3.22). This
variation was also found to an even greater degree in re-
lation to mental health and diabetes. For example, using
all data, 25% of CCGs had a mean rate of recruitment in
mental health of 0.44 or lower (compared to a mean of
8.26), while in diabetes 25% of CCGs had a mean rate of
1.74 (compared to a mean of 14.61).
Table 2 also shows the numbers of recruits who would
need to be reallocated across CCGs and LCRNs, based
on our three groups of conditions and data types. In re-
lation to all conditions at the level of the CCG, the
Table 2 Descriptive statistics on recruitment
Primary care and trust data, CCG level Primary care and trust data, LCRN level Primary care data, CCG level
Recruitment rate*
Mean (SD), interquartile range (IQR) [25% and 75% centiles]
across CCGs/LCRNs
All conditions 19.56, [5.74, 23.52] 19.56, [16.25, 22.67] 3.22, [1.19, 3.59]
Mental health 8.26, [0.44, 13.83] 8.26, [6.31, 10.88] 0.77, [0.06, 0.68]
Diabetes 14.61, [1.74, 15.12] 14.61, [10.82, 21.95] 2.65, [0.18, 3.21]
Recruitment redistribution index¥
% (Redistributed recruits/total recruits) × 100
All conditions 43.3% (1,416,436/3,272,538) 12.0% (394,290/3,272,538) 36.2% (194,389/539,046)
Mental health 53.3% (117,133/219,966) 12.6% (27,856/219,966) 58.9% (12,091/20,538)
Diabetes 52.6% (115,949/220,647) 23.8% (52,473/220,647) 57.1% (22,838/40,030)
*Recruitment rate is calculated as the number of recruits divided by the number of people within each disease group
¥Redistribution index is the sum across areas of the absolute value of the difference between the actual and the equitable number of recruits, divided by two
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percentage was 43%, compared to 53% for mental health
and diabetes. The redistribution percentages were much
lower for the larger LCRN areas (12–24%).
Figure 2 shows the geographical distribution of re-
cruitment per 1000 people with the condition across the
195 CCGs in England (detailed figures are in Add-
itional file 1, Appendices 1a to 1f).
Figure 3 displays bar charts for all 9 analyses, with
units of analysis (CCG or LCRN) ranked by prevalence
of disease (detailed figures are in the Additional file 1
Appendices 2a to 2i). If the recruitment rate was aligned
with the prevalence rate, recruitment rates (plotted in
the Y axis) would remain constant as the underlying
prevalence increases (along the X axis).
In the first row of Fig. 3, data on all long-term condi-
tions showed broadly similar patterns, with higher rates
of recruitment in areas of lower underlying prevalence
in both CCG and LCRN analyses using all recruitment
data. When CCGs were analysed using primary care data
only, the patterns were slightly more complex, with
broadly similar recruitment across quintiles of preva-
lence, with the exception in the second lowest quintile.
In the second row of Fig. 3, data on mental health
showed a similar pattern of higher rates of recruitment
in lower prevalence areas at the CCG level. The patterns
were more mixed at the LCRN level. When the analysis
was restricted to primary care data alone, there was a
broad pattern of increasing rates of recruitment in areas
Fig. 2 Geographical distribution of recruitment per 1000 people across 195 CCGs
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of higher prevalence, although there was evidence of
misalignment in the lowest quintile of prevalence.
In the third row of Fig. 3, data on diabetes show a dif-
ferent pattern. The highest levels of recruitment are
among those CCGs with moderate prevalence, while
high rates of recruitment were found in LCRNs with
low, moderate and high prevalence.
Figure 4 shows the concentration curves for all long-
term conditions over a 5-year period (detailed figures
are in the Additional file 1 Appendices 3a to 3i). Using
all recruitment data and all long-term conditions, the
curves demonstrate a disproportionate concentration of
recruitment in lower prevalence areas which is consist-
ent over time. The curves for mental health and diabetes
are more variable but reflect the same trends.
Table 3 shows the redistribution indices over time for
each of the three condition groups. Redistribution indi-
ces for all conditions show only small changes over time.
The redistribution indices for diabetes and mental health
are more variable. The regression analysis of trends with
time as the independent variable shows a more marked
decrease in mental health in three of four datasets, while
the opposite pattern is evident in diabetes.
Discussion
Statement of principal findings
Between 2013 and 2018, rates of recruitment to health
research varied substantially across England. Across all
long-term conditions, and specifically, in mental health
and diabetes, there was evidence of a lack of alignment
between recruitment and disease prevalence, with evi-
dence of high rates of recruitment in some CCGs and
LCRNs with low prevalence of disease and lower rates of
recruitment in regions with the highest prevalence of
disease. However, the patterns of recruitment are com-
plex—areas with the lowest prevalence are not consist-
ently the highest recruiting over the 5-year time period.
The existence of substantial geographical variation in re-
cruitment which is not related to prevalence of disease
suggests that a key driver may be regional research cap-
ability rather than the suitability of the population for
research. This may have implications for the quality of
Fig. 3 Bar charts for CCGs or LCRNs ranked by prevalence of disease
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the research, and for the equitable distribution of the
benefits of participation [1, 2, 31].
Strengths and weaknesses of the study
Although access to detailed recruitment and prevalence
data at a national level is unique, the data have limita-
tions. Our analysis is focussed on applied health re-
search, and the NIHR portfolio does not capture all
applied health research. Studies on the portfolio are
assigned to clinical specialities based on the study popu-
lation and focus, but there may be studies which relate
to diabetes and mental health which are not coded as
such, and thus analysis by disease may be more vulner-
able to such misclassification. Applied health research
which does not consent participants (e.g., administrative
datasets) is not captured.
As noted, mapping of most of the CRN recruit-
ment data to CCGs is approximate, as recruitment
location is recorded. Mapping recruitment to LCRN
rather than CCG is more reliable, but less granular,
as LCRN areas are large and estimates of the align-
ment between prevalence and recruitment at such a
level may hide important relationships within areas.
Although primary care recruitment data can be
mapped more accurately to individual CCGs, this
represents only around 20% of recruitment. We have
assessed the consistency across these sources. The
fact that primary care data mapped to CCG shows
somewhat different patterns to the total data sug-
gests some caution in interpretation. Finally, the
spatial maps are not weighted by locality size, and
hence, rural areas dominate the maps. This makes it
easier to identify the areas, but takes no account of
population density.
Data on disease reflects prevalence of long-term con-
ditions captured in general practice systems only, fo-
cussed on long-term conditions which account for
much health care activity [32, 33]. This allowed us to
use more precise, timely and comprehensive informa-
tion for determining prevalence at a local level. How-
ever, we have assessed prevalence, not burden of
disease, associated disability or the distribution of risk
factors [34, 35]. Measurement of prevalence through
the QOF has limitations. First, QOF includes data only
for certain chronic conditions and our measure of need
does not fully capture overall burden. Second, we were
unable to measure multimorbidity and used an aggre-
gate measure of disease burden assuming that burden
is additive. Multimorbidity may be associated with
higher or lower impact depending on the conditions
involved [36, 37]. There is no strong consensus on the
optimal ways to describe patterns of multimorbidity.
Although our method of dealing with multimorbidity
would influence estimates of disease prevalence, it
Fig. 4 Concentration curves for recruitment
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would be less likely to affect our assessment of the
links between prevalence and recruitment unless pat-
terns of multimorbidity varied by geography. Our data
on disease burden does not capture incidence which
may be more important in certain clinical areas. The
data may also be subject to the effects of associated
financial incentives which may impact on case finding.
Despite these limitations, QOF data are the only
source of information of prevalence of disease on a na-
tional and comprehensive basis. Future analyses could
explore alternative measures of disease prevalence,
such as per capita, measures of deprivation, and by
synthetic measures of burden. Collection of data on
recruited patient’s place of residence would also allow
more accurate analysis of the link between research
activity and burden.
Meaning of the study: possible mechanisms and
implications for clinicians or policymakers
The stimulus for this research was the proposal that re-
search delivery was poorly aligned with need [14]. This
has been our focus, although it should be noted that re-
search in general and clinical research in particular
could be less than optimally distributed across patient
populations, among disease severity within the patient
population, across clinical providers and across research
organisations. These distinctions are important because
the impact of each (and the ways to remedy this) may
differ. Interpretation is also dependent on a number of
issues. These may include the reliability of our preva-
lence measures by region as well as over time, alongside
value judgments about what recruitment activity should
look like across a service, region or population.
Although we have assumed that recruitment should
reflect underlying prevalence of disease within a region,
this is complicated by the organisation of services within
the NHS. People with particular conditions (e.g. specific
cancers) may travel out of region to specialist research
centres. Such centres may be located in lower prevalence
regions for that condition while serving bigger, possibly
more severe members of a disease population. The im-
portance of the geographical distribution of research
may vary by the type of research and may be less of an
issue for surgical interventions and short-term out-
comes, where potential confounders like socio-economic
deprivation may have less impact.
Table 3 Trends in the redistribution of recruits over time, 2013–2018









2013–2014 46% 39% 9% 18%
2014–2015 44% 44% 15% 19%
2015–2016 44% 45% 13% 19%
2016–2017 45% 42% 14% 18%
2017–2018 43% 42% 11% 24%
Trend† −0.60 0.41 0.25 1.00
Mental health
2013–2014 56% 75% 22% 54%
2014–2015 59% 72% 21% 46%
2015–2016 57% 72% 13% 50%
2016–2017 59% 69% 16% 40%
2017–2018 56% 53% 13% 31%
Trend† 0.04 −4.86 −2.22 −5.08
Diabetes
2013–2014 56% 58% 36% 28%
2014–2015 55% 67% 25% 47%
2015–2016 59% 72% 26% 52%
2016–2017 57% 74% 26% 52%
2017–2018 60% 74% 27% 62%
Trend† 1.08 4.04 −1.65 7.13
† Trend parameter represents the linear trend in the redistribution index. All trends are statistically significant (full data are presented in Additional file 1,
Appendix 4). Patients can be redistributed from over-recruiting areas to under-recruiting areas and vice versa according to the direction and magnitude of effects.
A positive trend indicates that the percentage of recruits needing re-distribution is increasing (i.e. that alignment between recruitment and prevalence is worse)
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There are a variety of other issues to take account of.
The NIHR Clinical Research Network has an underlying
philosophy of equality of access to research opportun-
ities and there may be tensions between that mission
and measures to re-align recruitment activity with popu-
lation prevalence. Equally, there may be an argument to
encourage disproportionate recruitment in some areas
beyond that which prevalence would suggest. It is im-
portant to note that there are other factors beyond
prevalence to consider when judging the external validity
of applied clinical health research, and recruiting in high
prevalence areas may still be prone to selection bias.
Although there are significant potential benefits to ensur-
ing that research populations represent the underlying
population of need, recruitment in areas which have not
traditionally been active in recruitment may be more costly
(for example, if there is less infrastructure). This may have
consequences for the volume, quality and rapidity of re-
search delivery. Although high internal and external validity
remains the goal of applied clinical research, these require-
ments can be in competition (especially in the context of
limited resources) and it is difficult to judge the relative im-
pact of reductions in internal and external validity.
Conclusions
These findings could act as a stimulus to developing a
broader understanding of what it means for research ‘to
be conducted with and in the populations most affected’
[14] and the development of indicators to assess the fit.
Perhaps more importantly, these data could support
ongoing assessment of policies which aim to encourage
better fit between recruitment and disease burden. Ana-
lyses of redistribution using all data at the level of the
LCRNs may provide the most reliable estimate of the
amount of redistribution required. This would suggest
that around 12% of the current recruitment activity
could be modified to align better with disease preva-
lence, although we expect that this would be a lower
bound, reflecting the limited granularity of data in the
analyses at the LCRN level. Although further modelling
is required to understand these relationships, there is
also a need to understand how better alignment might
be achieved. Recruitment remains an ongoing problem
[4, 38], and the evidence about how best to improve re-
cruitment is limited [39, 40]. There is a need to explore
what sorts of interventions can enable better realign-
ment (such as changes in how studies are funded,
changes to network organisation, or by modifying incen-
tives for research and clinical teams). The NIHR Clinical
Research Network in England is in a unique position to
be able to assess the relationship between recruitment
and prevalence of disease. The experience in England
may have implications for health care and research fund-
ing organisations worldwide.
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